BACM
PTCT icon

Blue Arrow Capital Management’s PTC Therapeutics PTCT Stock Holding History

Blue Arrow Capital Management’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-13,500
Closed -$353K – 206
2014
Q2 		$353K Sell
13,500
-2,500
-16% -$53.5K 0.05% 123
2014
Q1 		$418K Buy
+16,000
New +$430K 0.06% 96

Other funds holding PTCT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BCPEM
Bain Capital Public Equity Management Boston, Massachusetts $1.05B AUM 25.71% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Blue Arrow Capital Management's PTCT Position: Q3 2014 in Review

Blue Arrow Capital Management sold out of PTC Therapeutics (PTCT) in Q3 2014, closing a stake of 13,500 shares — an estimated $353K sold.

Blue Arrow Capital Management first reported a position in PTCT in Q1 2014 and held it in 2 quarters. The position peaked at $418K in Q1 2014. 99 funds tracked by Wall St. Rank hold PTCT as of Q3 2014.

  • Blue Arrow Capital Management reported no remaining PTC Therapeutics position as of Q3 2014 after selling out during the quarter.
  • Blue Arrow Capital Management sold 13,500 PTC Therapeutics shares in Q3 2014, an estimated $353K.
  • Blue Arrow Capital Management first reported a position in PTC Therapeutics in Q1 2014 and held it in 2 quarters.
  • Blue Arrow Capital Management's PTC Therapeutics position peaked at $418K in Q1 2014.
  • 99 funds tracked by Wall St. Rank held PTC Therapeutics as of Q3 2014.

Based on Blue Arrow Capital Management's 13F filing for Q3 2014, filed 14 Nov 2014.